Eli Lilly and Co
Eli Lilly blows past quarterly estimates, hikes outlook as Zepbound and Mounjaro sales skyrocket
David Ricks, chief executive officer of Eli Lilly & Co., at the Semafor World Economy Summit during the International Monetary Fund (IMF) and World Bank Spring meetings in Washington, DC, US, on Friday, April 17, 2026. Aaron Schwartz | Bloomberg | Getty Images Eli Lilly on Thursday reported first-quarter earnings and revenue that blew past […]
Read More
Inside India newsletter: AI is exposing cracks in India’s growth story as it hits high-paying IT jobs
Hello, this is Priyanka Salve, writing to you from Singapore. Welcome to the latest edition of “Inside India“ — your one-stop destination for stories and developments from the world’s fastest growing large economy. Over the past two decades, India’s IT sector has been driving a consumption boom that has in many ways anchored the India growth story. […]
Read More
S&P 500 futures tick higher after ‘Mag 7’ titans Alphabet, Amazon report earnings: Live updates
Traders work on the floor of the New York Stock Exchange (NYSE) during Pershing Square Capital Management LP’s initial public offering (IPO) in New York, US, on Wednesday, April 29, 2026. Michael Nagle | Bloomberg | Getty Images S&PP 500 futures were near the flatline on Wednesday night, following the release of quarterly reports from […]
Read More
Can AI outperform doctors? Experts weigh the pros and cons
Cravetiger | Moment | Getty Images You may already be familiar with AI taking notes in your doctor’s office, or being used to help book appointments or analyze medical images. But some experts believe consumers should be using AI even more to help understand their health. “People should be using AI much more than they […]
Read More
Pharma bets a little-known form of cholesterol will underpin its next blockbuster heart drugs
Pharma thinks it’s found the next frontier in preventing heart attacks. Novartis, Amgen and Eli Lilly are among the drugmakers betting that slashing levels of a particularly bad form of cholesterol could deliver the next blockbusters in cardiology. All three of the pharmaceutical giants are in late-stage trials to test whether drugs that cut Lp(a) […]
Read More
WHCD shooting, DOJ ends Powell probe, Musk vs. Altman and more in Morning Squawk
This is CNBC’s Morning Squawk newsletter. Subscribe here to receive future editions in your inbox. Good morning. We have a big week ahead of us: In addition to earnings reports from key automakers and five of the “Magnificent Seven,” the Federal Reserve will make its next monetary policy decision and the trial between Elon Musk and Sam […]
Read More
Cramer’s week ahead: Record highs meet a pivotal week for tech earnings
Key Points CNBC’s Jim Cramer said the market has become a “beast”, driven by a powerful rally in data center and AI-related stocks. He then turned to the week ahead, where a packed slate of tech earnings will test whether the surge can continue or if expectations have gotten too high. CNBC’s Jim Cramer said […]
Read More
Stocks making the biggest moves midday: Intel, AMD, Charter, Hims & Hers, Eli Lilly and more
Check out the companies making the biggest moves in midday trading: Comcast , Charter Communications — The NBCUniversal parent tumbled nearly 8% after a Deutsche Bank downgrade to hold from buy. Analysts at the bank said that, “there’s visibility into a return to sustainable revenue, EBITDA, and [free cash flow] growth; we do not expect […]
Read More
European stocks fall as ceasefire optimism fades; Novo jumps after Lilly weight loss pill prescription data
A bear statue stands outside the Frankfurt Stock Exchange on April 7, 2025 in Frankfurt, Germany. Florian Wiegand | Getty Images European stock markets finished lower on Friday, as uncertainty over U.S.-Iran peace talks weighed on investor sentiment. The pan-European Stoxx 600 closed the day down 0.6%, with most regional sectors and major bourses in […]
Read More
Roche CEO laments Swiss franc strength as drugmaker doubles down on U.S. investment
Roche reported falling sales in the first three months of the year, as the strength of the Swiss franc and generic competition for some of its older drugs weighed on the drugmaker. First-quarter sales came in at 14.7 billion Swiss francs ($18.7 billion), down 5% year-on-year — but up 6% on a constant currency basis. […]
Read More